Good morning.
Futures slightly green but defensively tilted — NDX +0.3%, SPX flat. IREN +7% leading the AI infrastructure pack, MMM +6% on the split announcement. GOOGL +2% following that Gemini 3.6 Flash release (weak reception, but investors don't care about model leaderboards anymore — they care about distribution). Rates creeping up after the ORCL Wisconsin credit story broke.
Asia constructive but cautious. Nikkei +0.4%, Seoul semi exporters ripping on that 181% YoY export surge for the first 20 days of July. Taiwan semi orders +84% YoI — the fastest pace on record. This is the real AI tape, not the headline drama.
Three themes framing the day:
1) THE VERA RUBIN WAVE IS HERE. The Information's report on 1,000 racks/day capability changes the calculus on NVDA's ceiling ($630B/quarter potential). But the more interesting angle is Vera CPU — 2.2x agentic throughput benchmarks picking a direct fight with CPU chiplets. NVDA expanding its compute monopoly beyond GPUs. PMs need to think about who loses in that world (AMD? CPU-centric names?) not just who wins.
2) COUNTERPARTY CREDIT BECOMES THE BOTTLENECK. ORCL's Wisconsin situation is a case study — BBB- credit rating triggers $7bn letter of credit requirement on a $1GW site backing the $300bn OpenAI contract. Twenty-four states now have large-load tariffs designed to prevent ratepayer backstopping of AI capex. This is a real constraint on buildout timing for sub-A- developers. Not sure we can read too much into single-site issues, but the structural implication for buildout velocity is underappreciated.
3) META'S CUSTOM SILICON DIVERGENCE. Meta's AMD MI400-series chip optimized for recsys at half the size of MI455X with ~144GB HBM (vs 432GB). Purpose-built silicon for specific workloads — not generic GPU builds. This accelerates the thesis that hyperscalers will increasingly own their inference silicon, which has implications for everyone in the merchant silicon supply chain.
We'll hit up IREN (best risk/reward in the neo-cloud space given the Vera Rubin delivery timeline), LRCX (semi equipment still the cleanest play on this buildout), and GOOGL first (need to sort out what the 3.6 Flash release means for the narrative — probably nothing, but gotta check positioning). Then get to enterprise software — CRM, ADBE, WDAY all with ARW scores suggesting re-rating risk.
The narrative is shifting. Rothschild Redburn just dropped a $1,000 price target — the highest on the Street — and it's NOT about AI glasses. It's about Meta quietly pivoting from a consumer assistant to a small business AI tool. That's the new story. The glasses stuff is real, but it's table stakes. The re-rate case is about distribution moats + SMB SaaS economics.
PT range is WIDE: $720 (BMO, Market Perform) to $1,000 (Rothschild, Buy). Consensus clusters around $800-835 (Jefferies at $825, BofA at $835, Raymond James at $850). That's a 25-50% upside from current $645. The bull case is accelerating; the bear case is getting squeezed.
Rothschild's SMB AI thesis is the incremental piece no one else is talking about. They see Meta building an end-to-end ecommerce operating system for the 250M businesses already on its platforms. That's not just advertising — that's storefronts, payments, CRM, ad creation. They peg the revenue opportunity at $209B+ EX-CHINA with a 45% IRR on the product. That's higher than core ads or an AI cloud business.
Raymond James adds the compute angle. They're leaning into Meta entering the cloud/API business — citing an API launch and a potential Meta-Anthropic deal. Backup revenue stream if the other AI bets underperform. Also a way to repurpose that massive data center buildout.
Jefferies keeps the glasses story alive with real numbers. 7M units sold in 2025. EssilorLuxottica doubling production to 20M in 2026. Daily glasses users tripling YoY. They see $14-18B hardware revenue at Apple Watch-like adoption. First-mover advantage, 82% GP margins on hardware. That's not nothing.
What's already known: The cost narrative. BMO at $720 is the holdout — they're worried about 2026 capex. Baird (Outperform, $830) says the high spend is baked in but the revenue benefits aren't. Market knows Meta's spending big; debate is whether it buys optionality or bleeds.
Bull: This is a platform economics story disguised as a social media stock. 250M businesses, 1B AI MAU, 82% GP margins on hardware, AND a potential SaaS/SMB pivot. Rothschild's math works because Meta already has distribution — they don't need to acquire SMB customers, just convert them. The capex scare is temporary. The legal headwinds (Snap settled, Meta now sole defendant in addiction trial) are manageable noise.
"Meta's opportunity derives from its distribution... 250 million businesses already on its platforms... a pivot to a small business AI tool would unlock a revenue opportunity of over $209 billion excluding China." - Rothschild Redburn
Bear: $1T market cap is discounting a lot that hasn't happened yet. The SMB AI tool is hypothetical. The cloud business is speculative. The glasses are nice but at 35-45M units, that's a fraction of revenue. BMO's $720 PT flags the real risk: 2026 capex is a gut-check moment. And Meta is now the only big tech defendant in the social media addiction trial — Snap settled, YouTube settled, TikTok settled. That's a spotlight no one wants.
"Concerns over Meta's projected capital expenditure for 2026 despite recent AI developments." - BMO Capital Markets ($720 PT, Market Perform)
"Meta's AI glasses are the only player now shipping at scale... first-mover advantage in a $14-18B hardware opportunity." - Jefferies (Brent Thill)
"Meta Compute would provide an alternative revenue stream if Meta AI, SMB Business Agents, or Meta Model API inference demand falls short." - Raymond James (Josh Beck)
"A pivot to a small business AI tool would unlock... inflecting return on invested capital. Regulation is widening the moat, reducing competition and lifting structural margins." - Rothschild Redburn
This is a platform vs product trade. If Meta pulls off the SMB AI pivot, it compresses the valuation gap with Microsoft and Google — both of which trade at 30x+ on AI optimism. Meta at 23x with accelerating revenue growth (26% LTM) and expanding margins is cheap if the narrative holds.
For hardware peers: SNAP settled the addiction suit (tentatively) but has no glasses scale. GOOGL has Gemini but no hardware distribution. AAPL is late to the AI wearable party. Meta owns the category for now.
The real read-through is B2B SaaS: if Meta can embed itself as the operating system for 250M small businesses, that's a structural re-rate. Think $CRM or $NOW multiple compression risk — or an entirely new addressable market no one's modeling.
Bottom line: The $720 floor is BMO's capex worry. The $1,000 ceiling is Rothschild's SMB SaaS dream. The stock trades in the middle because the market hasn't decided which Meta shows up in 18 months. I'd lean the bull case — distribution wins, and Meta has the best distribution in the world.
Verdict: IREN is printing the AI narrative hard — raised 2026 ARR target to >$4B (from $3.7B), signed $2.8B in new cloud contracts, 85% now under contract. The bull case writes itself: demand exceeding supply, pricing power visible in new deals at $15M/MW vs. prior Nvidia contract at $10M. But the stock is still 48% off its 52-week high ($40 vs $77). Market wants proof of execution, not just backlog growth.
Two analysts updated after the raise. Citizens (Miller) kept Market Outperform, $80 PT — that’s ~5.5x FY2028 EV/EBITDA, implying near-double from here. Goldman (Neutral, $50 PT) acknowledged the news is favorable but sees limited upside given current valuation and rising opex (marketing spend, wind-down of Bitcoin mining). Consensus is Buy (1.62) with PTs from $41 to $126 — wide range tells you the debate is alive.
Key numbers to know: the $2.8B in new TCV includes Perplexity and Figure AI alongside Microsoft and Nvidia. Weighted average contract duration ~4 years, new deals ~3 years. Customer prepayments covering ~45% of associated GPU capex — this is the real signal. It de-risks IREN’s own capital outlay and shows customers are willing to front money to secure compute. Needham (Hold) noted demand from hyperscalers, enterprises, and frontier labs still exceeds available and planned capacity.
Goldman’s take: the new contracts add ~$1B in incremental revenues over ~3 years. They also flagged the wind-down of Bitcoin mining (ending through 2026) which lowers cost but also removes a revenue stream.
Bull: Deployable AI compute is scarce, pricing is improving, and IREN has a clear line of sight to >$4B ARR with 85% contracted. Prepayments reduce funding risk. The $80 PT implies massive upside, and the stock has already returned 122% in the last year. This is a pure-play AI infrastructure and it’s cheap relative to hyperscaler multiples.
Bear: Cash burn is real — the company is aggressively expanding, and Goldman sees higher costs in FY2027 from marketing. The stock is down 48% from its high for a reason: the market thinks the bull case is mostly priced in. $50 PT from Goldman suggests a ceiling, and the $126 high-end consensus feels like a lottery ticket. If demand softens or hyperscalers pivot to internal builds, IREN’s backlog might not convert at these margins.
Citizens analyst Greg Miller, from their note:
“The announcement provides further evidence that deployable AI compute capacity remains scarce.”
That’s the core thesis in one line. The prepayment structure is the mechanism that makes it real.
Mixed bag on the Personalis deal. Two buys, one underperform. The bull camp sees a strategic MRD land grab. The bear thinks it’s a tell on slowing core diagnostics. Stock down ~13% in a week, now ~$48.50. PT range $35–$100. That spread alone tells you the debate isn’t settled.
Tempus announced an all-stock acquisition of the remaining 81% of Personalis (PSNL) for $1.7B EV ($1.5B net of existing stake). 28% premium to PSNL’s 30-day VWAP. Cash option for 50% of consideration. Expected close late ’26 / early ’27. The prize: tumor-informed NeXT Personal MRD test — already reimbursed in four Medicare indications. Tempus was the exclusive commercialization partner; now they own the whole thing.
Canaccord ($80) and Needham ($75) both Buy. Thesis is straightforward: MRD is a $20B+ TAM with <10% penetration. Personalis brings the best-in-class tumor-informed assay. Tempus brings the commercial engine — scale, data, pharma relationships. Needham explicitly says “buy any weakness related to the transaction.” They see tighter data integration as a synergy multiplier for the Insights business (the higher-margin pharma services piece). Revenue growth is a blistering 70% LTM — but yes, not profitable this year.
Jefferies ($35, Underperform — low-end of the range) is the lone dissenter, and they have a pointed argument:
“Jefferies expressed concerns about whether the rationale for the acquisition is intended to offset a slowing core diagnostics business.”
The sting: at the May 29 analyst day, management said this specific deal would provide no net income benefit. Now they’re doing it anyway. Jefferies is “constructive on the science” but sees the move as defensive, not offensive. Also worth noting — Freedom Capital started with a Hold at $59. So not everyone is all-in.
Guggenheim bumped PT to $65 (Buy) after a management meeting — just updating models. Tempus also inked a data collaboration with Angiosarcoma Awareness and published a validation study for its AFib prediction software. Nice to have, but the MRD deal is the only story today.
Bottom line: You’re buying a story about a massive underpenetrated market and a commercial machine that can accelerate adoption. The risk is you’re buying a company papering over deceleration with an expensive stock deal. The 70% revenue growth buys some credibility — but the cash burn and “no net income benefit” comment hang over the narrative. If you believe MRD is the next oncology standard, the pullback is the entry. If you think the core is slowing, $35 looks right.
Verdict: Data Center accounting is a $200M+ hangover that won't clear until FY28. The bull case lives at the Cloud reacceleration and AI agent monetization — but near-term EPS is a mess. Stock down 52% in a year for a reason.
Two notes this morning, same theme: FY27 revenue estimates are coming down as the Data Center pull-forward from FY26 creates a nasty comp. Raymond James reiterates Outperform but cuts FY27 rev growth to 10% YoY (from higher), modeling Data Center down -14% vs. prior -7%. Their call: Street consensus at only -5% is not accounting for the full magnitude of the EOL recognition benefit that won't repeat. $200M+ headwind — that's the number to remember ($170M communicated in Q1 plus another $50M in Q3 of FY26).
BofA is more bearish (Neutral, PT to $105 from $110), cutting FY27 revenue by 4.3% and FY28 by 4.1%. They now see FY27 total rev of $7.174B (11% growth) vs. consensus $7.373B (14% growth). The guide vs. consensus is the near-term catalyst — above and you rally, at or below and you're dead money given weak software sentiment.
Bull case (Raymond James, Bernstein, Truist): Cloud growth reaccelerates to 20%+ in FY28, Data Center stabilizes, and AI coordination tools (Jira agents, Team 26 event) provide a new monetization vector. FY28 total subscription ARR growth ~17% — mid- to high-single digit net new ARR. Multiple at 11x EV/FCF on CY27 is not demanding if you can see past the DC noise.
Bear case (BofA, Citizens): The $140B TAM narrative is fine, but FY27 is a dead zone. Street still too optimistic on DC trajectory, software sentiment is horrid, and the AI tailwind is unproven in the P&L. Citizens' survey had 7 positive vs 11 negative data points — not exactly a vote of confidence.
Raymond James nails the accounting trap:
"Data Center accounting nuances will create a $200 million-plus headwind to fiscal 2027 from year-over-year comparisons that do not repeat."
That is the single most important data point in the TEAM story right now. Until the Street properly models that clawback, every quarter will be a game of "beat and lower." Not a fun setup for PMs who like clean comps.
TEAM is a FY28 story trading on FY27 data. The risk/reward is asymmetric to the upside if you believe Cloud reacceleration is real (and you have patience for a year of noise). But for a multi-manager book, this is a names-you-watch-not-own situation until the guide clears the air. The AI agent narrative is real but still pre-revenue impact — don't pay up for it yet.
Verdict: HUT is working. The Nvidia option exercise on Beacon Point Phase 2 is the kind of validation that actually moves the needle. This isn’t a speculative land grab – it’s a 15-year, $9.8B lease with a tenant that knows what it’s doing. The stock’s up 323-373% in a year, but the narrative just got materially de-risked.
Nvidia didn’t just renew – it doubled down. The option on the remaining 352 IT MW at Beacon Point was exercised near the end of the exclusivity window, bringing total signed capacity to 704 MW. That’s a full commercialization of the campus (1,000 MW utility capacity, so there’s still headroom for additional phases).
Economics are clean: Needham estimates $1.86M per MW NOI over the average 15-year triple-net lease. That’s in line with CIFR/WULF comps and better than what APLD/CLSK got on their 2026 leases. The second phase ramps in Q2 2028.
Both Needham and Rosenblatt raised 2028 estimates. Needham now sees $1.70B revenue / $1.32B EBITDA (was $1.44B / $1.07B). Rosenblatt goes a bit higher on revenue: $1.8B / $1.1B EBITDA (was $1.7B / $1.0B). Variance likely driven by different ramp timing assumptions and NOI per MW haircuts.
The two PTs diverge – Needham’s $145 (19x 2028 EV/EBITDA) vs Rosenblatt’s $124 (14.7x). That spread reflects disagreement on terminal multiple, not on the asset quality. The stock’s at ~$101. I’d lean toward the higher end given the recurring, contracted nature of the cash flows and the credit quality of the counterparty.
Bull case: HUT has proven it can secure top-tier HPC tenants on attractive terms. The Nvidia deal validates the partnership-driven delivery model across River Bend and Beacon Point. If they can replicate this across their broader pipeline, the book value of contracted MW is worth multiples of current EV. Rosenblatt explicitly says the expansion “demonstrates the success of Hut 8’s partnership-driven delivery model” and “increased confidence” in replicating it.
Bear case: The stock is still unprofitable, revenue growth is 115% LTM but burns cash. Beta of 6.07 means it’ll get wrecked in any risk-off move. Insider sales are real – CLO Victor Semah sold $1.25M worth, total insider sales hit $5.7M. That’s not a thesis breaker, but it adds noise. And if Nvidia is the only HPC tenant in town, that concentration risk is non-trivial.
“The economics for both Phase 1 and Phase 2 at the Beacon Point site remain unchanged, representing $1.86 million per megawatt in net operating income over an average 15-year triple-net lease. These terms align with CIFR and WULF deals and exceed APLD and CLSK economics on their 2026 leases on a NOI per megawatt basis.”
The $5.7M of insider selling is mostly pre-planned 10b5-1 or tax-related. CM for a $10B+ market cap company, that’s meaningless in the grand scheme. But PMs will ask, so flag it. Don’t let it distract from the real story: contracted MW + strong counterparty = cash flow visibility. That’s what matters.
Verdict: CRM is a tug-of-war between a bull case built on Agentforce traction and a bear case questioning when that traction actually hits subscription revenue. Stock's down 34% YTD, currently trading at $173 — BELOW Morgan Stanley's freshly cut $185 target. The bull camp has a data point from the channel. The bear camp has the actual numbers. Right now, the numbers are winning.
Raymond James is holding the bull flag — reiterated Strong Buy, $290 target. They hosted a webinar with a leading CRM SI partner that's deployed Agentforce across its customer base. The partner cited "slightly better than expected demand" in 2026. The friction around AI/agentic scrutiny that defined 2025 has eased. Key nuance: demand is diversifying beyond Service Cloud into other workloads, and adoption is NOT coming with headcount reduction (which would cannibalize seat-based revenue).
Morgan Stanley flipped the script entirely. Adam Wood cut to Equal-weight from Overweight, slashed target to $185 from $287. His thesis: strong AI momentum is real, but subscription revenue growth continues to soften. Commerce and Tableau remain structural drags. He's not questioning the strategy — Salesforce is one of the few SaaS companies actively decoupling its data/workflow layers from the UI — but monetization is too nascent to underwrite.
"The partner referenced slightly better than expected demand trends in 2026... Agentforce adoption has not been met with a corresponding reduction in headcount." — Raymond James channel check
Bull case ($290+): Agentforce is real, diversifying, and not cannibalizing. Partner feedback shows demand acceleration in 2026 vs. 2025 skepticism. At 19.7x P/E and a PEG of 0.51, the stock prices in zero AI upside. Any sustained subscription revenue inflection = massive multiple re-rate. Win-backs from private competitors (Sierra) on pricing dynamics.
Bear case (sub-$185): Until Agentforce offsets Commerce/Tableau decay, subscription revenue stays flattish. The decoupling strategy is correct but creates a messy transition period. MS calling for range-bound trading absent a "notable growth inflection." CLSA initiating at $165 (Hold) reinforces the "show me" camp.
The channel feedback is the best data point the bulls have right now. It's directional, not hard — but it's from a partner that's actually deploying. The bears have the financials: subscription growth deceleration, forward-looking metrics deteriorating. This is a classic "good news for 2027, bad news for next quarter" setup.
Key debate: When does Agentforce show up in subscription revenue? Not Q2. Probably not Q3. If MS is right that it's 2027+ before it's material, the stock stays in no-man's land until that catalyst gets closer. At 19.7x with a 34% YTD decline, some PMs will buy the channel check. Equally valid to wait for the numbers.
Other analyst actions this week: Goldman at Buy/$242, Evercore at Outperform/$250 (cut from $260), CLSA at Hold/$165. Wide dispersion tells you everything about the uncertainty.
Positioning take: Not a strong recovery play until we see subscription revenue stabilize. The SI partner data is encouraging but doesn't change the Q2 setup. Range-bound feels right until the next print.
**VERDICT: The hardware trade is alive and well. Morgan Stanley just capitulated — upgrading from Underweight to Equalweight — but they're still late to the party. Stock's up 112% in six months, trading $160 vs their new $133 target. The real question isn't "is hardware good" — it's "what's the software monetization timeline?"
Morgan Stanley finally threw in the towel on their Underweight call. Their thesis (FTNT is a hardware/networking story, not software) was "more accurate than expected" — accelerated hardware buys for memory pricing and AI preparedness drove the outperformance. They're now Equalweight with a $133 PT, up from $80.
The key line: checks point to healthy hardware sales and fear of purchase pullforward has not yet outweighed enthusiasm. That's the tension right now — are we pulling forward years of demand into Q2 and H2, or is this a durable cycle? MS isn't sure, but they don't see Q2 as a negative catalyst.
Caveats they flagged:
Also today: FTNT announced Security Processor 6 with Intel. FTNT becomes the first publicly named external customer for Intel 4 process technology — that's a real validation point. Intel provides design, packaging, manufacturing.
From William Blair (Market Perform, no change):
"The partnership with Intel is designed to advance Fortinet's long-term silicon roadmap...custom security processors remain central to Fortinet's product strategy and differentiated hardware architecture."
This isn't a near-term revenue driver — the note is about roadmap credibility. FTNT has spent 20+ years building custom silicon rather than using off-the-shelf chips. The Intel deal says they're doubling down, not pivoting. For a hardware-led bull case, that's supportive.
Bull: Hardware cycle is real and durable — AI infra buildout, OT security upgrades, memory-driven refresh cycles. The installed base is expanding, and eventually software attach will follow. At 47x forward earnings you're paying for that eventual monetization, but if hardware stays strong, multiple compression isn't imminent.
Bear: You're paying 47x for 2027 earnings — more than 10x historical — for a hardware story with no proof software attach is accelerating. If hardware demand was pulled forward (and MS admits they can't rule that out), the comps get ugly. HSBC downgraded to Reduce at $102. The risk/reward is asymmetrically bad at these levels.
My take: The hardware momentum is real and the Intel partnership is strategically sound. But at 47x forward P/E for a company where software is still "show me" — this is a position-sizing call, not a conviction call. I'd rather own it after a pullback than chase it here. The Q2 print (eight days away) is the next key data point.
VERDICT: Two modest positives, one narrative. Evercore stays Outperform $365. The leasing news is a small incremental pull-forward mechanism for hardware revenue. The DOJ settlement chatter is a bigger deal – removes a multi-year overhang if it sticks. Neither moves the needle on the $4.8T market cap, but the sum of parts keeps the stock grinding near highs.
Leasing Program (Apple Upgrade, launches July 28, Klarna backing). Replaces the old iPhone Upgrade Program and standard financing. 24-month terms for iPhone/Watch, 36 for Mac/iPad. No AppleCare included. Apple raises monthly payments? No – they're lowering them vs existing options. This is a demand capture tool, not a margin driver. Evercore sees it as a small positive for unit volumes, especially on the high-end Pro models that get skipped in an upgrade cycle. The real read-through: Apple is getting more aggressive on financing to offset the $100+ price hike on Macs/iPads from rising memory costs. Net effect is neutral to slightly positive for ASP, slightly more pull-forward risk to revenue.
DOJ Settlement Talks. Early stage – exchanging draft materials, no trial date set. The lawsuit (filed March 2024) isn't about App Store fees or Google search payments (those are separate cases). It's about super apps, cloud streaming, cross-platform messaging, non-Apple watch interoperability, third-party wallets. Evercore calls it a "modest positive" – reducing regulatory overhang and avoiding a multi-year litigation distraction. The key variable is scope of remedies. If Apple has to open up iOS interoperability in a meaningful way, that's a services revenue headwind. If it's a fine + minor concessions, it's a nothingburger.
Bull case: Both developments remove friction. Lower monthly payments drive incremental iPhone/Mac upgrades. DOJ settlement removes a 2-3 year legal overhang, allowing the market to focus on the AI cycle (large installed base, on-device inference, services monetization). At 39x P/E, the narrative shift alone supports a $365+ target.
Bear case: Leasing just pulls forward demand – you're trading margin for volume on a product already near saturation. DOJ settlement could include real interoperability concessions that hurt Services growth. And the stock is already at 1% from its ATH. The risk/reward is capped until earnings (9 days away) deliver a beat that justifies the multiple.
Evercore on the DOJ settlement, directly:
"The ultimate impact will depend on the scope of any remedies or concessions Apple may have to make around iOS, product interoperability and services."
MSFT is the AI monetization story, and Morgan Stanley just stamped it with their biggest vote of confidence yet. Initiated Overweight with a $600 PT (16x FY28 GAAP EPS, 1.2x PEG) — squarely in the middle of the $525-625 cluster of targets we've seen from DB, CLSA, Evercore, and Wells. The bull case is $795 if Azure AI economics match Core Azure and Copilot drives M365 acceleration. Bear case is $250 if it's just another bare-metal provider stall-out. Wide range, but the house is betting on the former.
"Azure reflects monetization of infrastructure demand, while Copilot reflects monetization of AI at the application layer."
The team expects Azure growth to re-accelerate in 2H CY26 with Copilot adoption compounding. The gross margin trajectory is the real bogey here — that determines long-term earnings power and whether the AI capex delivers ROI. Current gross margin is 68% on 18% revenue growth. If margins hold or expand as AI scales, the $600 PT looks conservative. Key watchpoint: Wells flagged capacity costs as a risk but still maintains Overweight at $625. Net net: the narrative is shifting from "can AI monetize?" to "how fast and at what margin?" — and MSFT is the cleanest proxy for that answer.
OKTA IS THE PURE-PLAY WRAP ON THE THEME THAT EVERY PM NEEDS TO OWN. Bernstein’s mid-2026 CISO survey just dropped and the read-across is unambiguous – identity is the #1 budget priority, cyber spend is accelerating, and OKTA is the proxy. 43% of CISOs expect cyber budgets to outgrow IT, the highest reading in years, and software (identity, cloud security) is the biggest wallet share gainer. The stock is already up 72% YTD and trading near its 52-week high – the narrative is real, not just momentum.
“Identity security leader Okta (NASDAQ:OKTA), trading near its 52-week high with a year-to-date return of 72%, exemplifies this trend with revenue growing 12% and an impressive 77% gross profit margin.”
THE FUNDAMENTALS BACK THE MULTIPLE. Revenue beat by 1.7% last quarter, cRPO grew 12% YoY (above consensus), and the margin profile is pristine. Street is piling on – KeyBanc went to $175 (Overweight), Scotiabank to $135 after investor meetings, Cantor stayed at $125 (Overweight). All three citing the same narrative: AI agent security is the new incremental spend driver, and OKTA owns the identity layer.
THE SURVEY’S TAILWIND IS REAL. SecOps saw the biggest incremental spend increase vs. end of 2025; identity and threat intel close behind. GenAI adoption is forcing urgency – not a hypothetical future but a current budget reallocation. The only headwind: SSE showed incremental weakness, and endpoint security spending plans slipped despite a high baseline. But identity? That’s the part of the stack CISOs are adding to.
OUR TAKE: OKTA is a high-conviction long in a multi-manager book right now. The combination of a proprietary spend survey, a growing AI security narrative, and accelerating financials (12% rev growth, 77% GM) makes the risk/reward asymmetrical. The $175 PT from KeyBanc is the bull case, but even the consensus low-end ($125) gives you minimal downside from here. We’d be buyers on any pullback – the CISO survey is the best data point you’ll get all quarter.
Stifel just pulled the trigger on an upgrade — Buy from Hold, PT to $160 from $135 — after a ~30% drawdown from the highs created a better entry. The catalyst is real: GPU price increases announced Monday that should push revenue per megawatt into the mid-to-high teens percentage range. That’s a rate-of-change story, not just a valuation call. The debt-for-equity conversion also clears the deck for capacity expansion without blowing out leverage or diluting shareholders too badly. Cantor Fitzgerald is already Overweight at $177, so the Street is mostly leaning bullish here. UBS stays Neutral at $155, but that’s the outlier.
“With the stock down ~30% from recent highs and several incremental positive data points over the past week, including today’s GPU price increases that should support Rev/MW in the mid-to-high teens, and the recent debt-for-equity conversion that frees up financing for future capacity (while sustaining <4x leverage and capping dilution), we upgrade DigitalOcean to Buy.” — Stifel
Verdict: BULLISH. AWS reacceleration is the story, and the tape is not fully pricing it in. Telsey, Truist, and KeyBanc all in the same camp — AI workload adoption + Prime Day timing shift = beat-and-raise setup for Q2. The $315 price target from Telsey feels conservative given Truist at $320 and KeyBanc at $335, but the collective thesis is tight: AWS growth accelerating to 30% (Truist) and e-commerce share gains intact.
Key numbers: AMZN trades $249.99, ~$2.69T mkt cap. Telsey sees 17.5% sales growth and 24% operating income growth vs consensus 22.5% — that’s a bogey they think AMZN crushes. PEG of 0.82 makes the valuation feel cheap relative to the growth rate. Prime Day moved to June 23-26 from July 8-11, pulling revenue into Q2. Higher-margin ad/media/AWS revenue mix offsetting AI capex drag.
“Amazon should continue gaining market share through its Prime member base, small business relationships, and technological edge.” — Telsey
Biggest overhang? Dave Brown’s departure from AWS after 19 years — he ran compute and ML services. Not panic-inducing but a headwind for narrative continuity. The satellite venture (Project Kuiper / Amazon Leo) with Herotel is a 2027 story, not a catalyst today. Keep your eyes on the Q2 AWS print: Truist’s 30% growth call is the number to beat.
Verdict: Cloudflare is getting re-rated as the market finally sees the platform pivot beyond CDN/security. The stock’s 60% run in 6 months tells you this isn’t a secret anymore, but the analyst community is still playing catch-up.
The big move: Truist raised PT to $300 from $250 (Buy), joining a coordinated upgrade parade – Citizens to $330, TD Cowen to $300, Scotiabank to $300 with an upgrade to Sector Outperform. The collective thesis: NET is evolving from edge security into a "control layer" for identity, routing, security, compute, observability, and app workflows. That’s a $238B TAM in 2026, expanding to $329B by 2028.
"Cloudflare is processing hundreds of billions of agentic requests per month. The mix shift toward Workers and higher paid traffic pressured gross margin in Q1 FY26, but the trade-off is strategically constructive given potential to become a core application layer for AI-native workloads." – Truist
The tension: Gross margin compression from Workers mix is real – but PMs should view that as a deliberate investment, not a bug. NET is running unprofitable (negative EPS of $0.25 LTM), and the stock is bumping against the 52-week high of $291. The OpenAI research pilot for AI search indexing gives the narrative another layer – leverage 20%+ of websites behind NET’s network to improve AI answers. Massive optionality, but the market is already pricing in a lot of it.
Bull vs Bear steelmanned: Bulls argue NET is the only independent control plane that touches security, networking, compute, and AI workloads – a unique asset in a world where hyperscalers bundle everything. Bears point to the negative EPS and argue the TAM narrative is just repackaging old products. The rate of change favors the bulls right now (accelerating enterprise execution, three PT bumps in a week), but the risk/reward tightens at $280+.
PANW remains the street’s darling — William Blair out with Outperform as top pick, citing firewall pull-forward and AI-sec tailwinds. The note is the strongest channel check we’ve seen in weeks: customers rushing to buy firewalls ahead of expected price increases, supply chain constraints looming, and Mythos driving vulnerability management spend. Meanwhile, a parade of PT bumps to $330–$430 (Tigress, Evercore, Needham, FBN, Cantor) all anchored to Q3 beat and FY27 growth. Fair value models flag overvaluation (InvestingPro says so), but momentum is the only religion that matters here. PANW +92% IN 6M, TRADING NEAR $368 52W HIGH.
“Customers are rushing to purchase firewalls ahead of expected price increases as supply chain challenges loom in the background.” — William Blair
One watch: endpoint security and AI-security projects are taking a “step backward” as Mythos has drained both attention and budgets. That’s near-term headwind for adjacent names, but PANW’s firewall franchise is the immediate beneficiary.
UBS ups PT on FCF repurchase story — Arcuri sees MU generating >$400B in FCF through CY2028 (yes, that number appears in the note – we’ll flag the math later). LTM levered FCF was $26.2B. Repurchases locked until Dec 2026, then all FCF goes to buybacks. At current $990B market cap (that’s the article’s number – seems high for MU, but rolling with it), that implies a monster retire rate.
“At the current stock price, such buybacks could represent more than 40% of the company through calendar year-end 2028.”
Rest of the analyst chorus (KeyBanc, TD Cowen) leaning on memory tightness and pricing uptick. UBS angle is pure capital return math – less about cycle, more about FCF yield post-restriction. Worth sanity-checking the >$400B figure, but the directional thesis is clear: cash machine.
UBS GOING $58 FROM $37 — they see the data security story accelerating, not peaking. Shares have nearly doubled from April lows (YTD +44.7%), but still trade at a discount to where they were a year ago. That’s the setup: consensus is still priced for deceleration, but UBS thinks guidance is sandbagged and the $1B ARR target for 2027 is real — with margin upside on top. Add in the PE interest (Blackstone, Thoma Bravo, Vista circling) and you’ve got a stock that’s both an operational compounder and a takeout option.
"Another quarter of execution and conviction in calendar year 2027 ARR growth acceleration could help shares rerate beyond 30 times calendar year 2027 free cash flow for high teens growth."
Stephens also jumped to Overweight from Equal Weight (PT $45) on the same demand narrative. The M&A chatter is real — Varonis hired advisors to field PE pitches — but that’s gravy. The base case is an organic growth compounder at a still-reasonable multiple. Q2 earnings in seven days are the next catalyst. Risk: if they miss or guide soft, the double from April lows leaves little room for error. But the setup fights in their favor.
Wolfe doubles down: Outperform, $460 PT. The call is about ad resilience + cloud momentum — not political theater. Q2 demand stable despite macro hand-wringing, and the mid-terms + 2026 World Cup are specific catalysts for Search spend. WPP just raised its ex-political ad forecast to 8.9% YoY (from 7.1%). That’s a clear read-through.
Cloud is the real torque here. GCP share gains are AI-driven, demand still outstripping supply. And the $65B Anthropic raise (at a ~$965B valuation) is a direct OCI tailwind — Wolfe sees >$50B in other income contribution from that alone. Markets aren't pricing that in yet.
"Headline risks from OpenAI pose no threat to current estimates."
Earnings on July 22 — options market pricing a 5.1% move. Historically they’ve exceeded the implied move. Square that with a 26.9x P/E and a 0.57 PEG. You’re paying for growth that’s accelerating, not fading.
Truist stepping out to $182 (from $155) on CVLT – still a Buy, but the stock's already baked in the 22.7% six-month run. Thesis is straightforward: accelerating SaaS adoption, multi-product penetration, and a clean guide for FY27. Subscription revenue guided to $263-265M in Q1, with full-year ARR growth of 18-19% to ~$1.2B. Margins holding at ~20.5% non-GAAP. Committed to returning ~60% of FCF via buybacks – not a needle-mover, but keeps the floor firm.
"We expect management to maintain a prudent tone early in the fiscal year." – Truist's Junaid Siddiqui
That's the anchor: don't expect fireworks on the call, just steady execution. The Microsoft Azure partnership (cyber resilience as native service) and "Minutes to Recovery" simulation are incremental positives but not yet reflected in numbers. Stephens also raised to $155 (Overweight) – so the Street is broadly constructive, but the r/r is tighter post-run. Bull case hinges on continued SaaS mix shift and margin expansion; bear case says multiple is extended and competitive positioning vs. Cohesity/Dell is a live risk.
Verdict: Evercore stays Outperform, but the setup into earnings is "challenging" — the bullish case rests entirely on DRAM/NAND spend acceleration from Agentic AI, and Lam's 37% NAND exposure is the key lever. Stock is up 87% YTD vs S&P +10%. That creates a high bar. Street models have LRCX product revs growing 37% in CY26 and 32% in CY27, slightly below Evercore's WFE estimates of +40%/+38% — so there's room for upside if spending holds. Valuation is stretched at 39x earnings, an 80% premium to the S&P. But nearly every PM in Evercore's survey is already overweight semis equipment. Hard to push that much further without a catalyst.
"The fundamental backdrop remains strong for the group and Lam Research. Agentic AI is DRAM and NAND intensive, and Lam Research is positioned to benefit from acceleration in NAND spending with approximately 37% exposure."
Multiple shops raised PTs to $400-425 (Stifel, Mizuho, TD Cowen, Lynx) versus Evercore's stickier $355. Bull case rests on LRCX historically growing 11-35% faster than WFE in prior cycles — they're betting that spread widens again. Bear case: that 39x multiple is already pricing in perfection, and any WFE capex slowdown in H2 would hit hardest here given the NAND skew.
Morgan Stanley cuts to Underweight (PT $240 from $365) — and the stock is already trading below that ($234.74, -33% YTD). The bear case isn't just about GenAI substitution risk on Creative Cloud anymore. MS flags three new transitions that collectively raise execution risk: shift to freemium GTM, simultaneous CEO/CFO turnover, and moving from margin expansion to AI reinvestment. The 12x CY27 GAAP P/E prices in a lot of disruption, but the visibility on timing and magnitude of any turnaround is shot.
"The convergence of these transitions raises execution risk at a time when other software companies show clearer growth durability, operating leverage, or near-term AI monetization."
Not all analysts agree — HSBC upgraded to Buy ($308), CLSA launched Outperform ($300) — but MS has been ahead of the curve on this name before. They moved to Equalweight last fall citing GenAI risk, and now they're doubling down. The stock is cheap, but cheap doesn't work when the narrative is broken and leadership is in flux. Watch for the Topaz Labs acquisition to either reinforce the AI story or become another distraction.
THE PT CUT IS ABOUT MULTIPLE COMPRESSION, NOT A BUSINESS DETERIORATION. Needham slashed their target to $320 from $400 (still Buy) at 40x 2028 EPS vs the prior 50x — citing the across-the-board de-rating in AI semis. Stock is $215.58, down 13% this week but still up 383% over the last year. The fundamental story is intact: Q2 beat (ex-tax) and Q3 revenue guide slightly ahead, FY26 revs raised to >$600M (from $570M). Licensing is the kicker — management is keeping it conservative in guidance (no new licenses baked in), but the recent $60M two-year OEM deal shows the payoff is real.
"The adjustment follows recent multiple compression across AI semiconductor stocks." — Needham
That’s the whole ballgame. Execution is fine. Bull thesis: VICR is a unique power architecture play with licensing upside that isn’t fully discounted. Bear case: The stock already prices in a ton of success at 383% LTM, and if AI semis multiples stay compressed, the 40x forward looks rich without new licensing catalysts. The upcoming decision on the second ChiP fab is the next binary catalyst to watch.
TRUIST GOES TO HOLD ON R/R. After a ~60% YTD rip, the analyst sees limited upside from here. PT raised to $40 (from $27) but stock sits at $37.76 — barely any juice left. They still like the franchise (78% GMs, strong FCF, improving op discipline) but need to see Tenable One migration accelerate, better net retention, and real monetization from Hexa/AI before they get more constructive.
“The stock’s risk/reward has become more balanced, with limited upside to the revised price target and a medium-term financial profile that still requires clearer evidence of durable revenue acceleration.” — Junaid Siddiqui, Truist
JPMorgan is the lone bull — they bumped PT to $40 (from $35), Overweight, citing vulnerability volumes and new product adoption. But that’s the same $40 ceiling. The real question: can TENB break out of this valuation box? FedRAMP High + IL5 clearance and the OpenAI partnership (GPT-5.5 integration) are positive catalysts, but they’re not yet showing up in the financials. Stock needs to prove it can grow into the multiple, not just ride the narrative.
JPMORGAN RAISES PT TO $346 (FROM $267) — not a rubber stamp despite the stock being down 19% in the past week. They now have estimates through FY30 and are projecting 4.1 GW of product deliveries that year (supported by the expanded Brookfield partnership). The bull case hinges on contract catalysts — Wyoming/AEP, Oracle/New Mexico — not just the backlog.
The short report overhang is fading. JPMorgan notes Bloom’s blog post addressed the scandium supply concerns (enough to support 25 GW of annual manufacturing). That’s a real de-risking. Still, they’re waiting for more supply chain detail.
The macro setup helps. The firm explicitly flags that negative headlines about data center grid connections ahead of U.S. elections could be a relative positive for behind-the-meter players like BE. That’s a non-consensus catalyst — and it’s real.
“Potentially negative headlines regarding data center connections to utility grids ahead of U.S. elections could serve as relative positives for behind-the-meter participants such as Bloom Energy.”
Street targets are all over the place ($70–$390). Bulls like RBC ($335) are in the same neighborhood as JPMorgan; Mizuho ($285) and TD Cowen (Hold) are more cautious on valuation. The 56B market cap after a 677% run makes the r/r binary — either they deliver the GW ramp or multiples compress fast. JPMorgan is betting on the former. We’re watching for the next contract print.
Defense procurement executive order is incremental positive, but the real story here is tungsten pricing — spot APT (ammonium paratungstate) remains elevated on tight supply and semiconductor/defense demand pull. The stock already up 208% over the past year, but the analyst PTs keep moving higher (DA Davidson to $33 from $25, Oppenheimer to $25 from $22). The offtake extension (15→21 years, volume +40%) de-risks the revenue trajectory. Not a new thesis, just confirming the secular call.
"DA Davidson raised its price target from $25 to $33, emphasizing the company’s favorable tungsten outlook" — Analyst Matt Summerville
The order underscores the U.S. need for western primary supply of tungsten, with the prior stockpile believed fully depleted. That’s a multi-year structural bid. Risk: stock already pricing a lot of it — current price ~$14 vs $33 target, but the 208% run means PMs need to decide if the narrative is still early or late innings. I lean early-to-mid cycle given the supply deficit and defense pivot, but watch for any APT spot softening.
This is all about the first print. JPMorgan keeps their $44 target (60% upside from $27.47) but the stock has given back 11% in the past week — classic behavior into a first-ever earnings report as a public company. The expansion story (3.5 GW base to 10 GW by 2030) is the narrative. The question is whether the debut guide is conservative enough to reset expectations.
"The upcoming earnings report represents the first opportunity for the market to evaluate the IPO narrative against actual results."
Five firms have now initiated or reiterated buy/overweight ratings (targets $42-$47 cluster). Deutsche is the lone hold at $41 on valuation — not a thesis break. The real bogey is capacity expansion, specifically hitting that 5 GW run-rate by year-end 2026. Order intake and backlog conversion are the near-term tells, but the service attach rate and margin expansion in the install base is the longer-term r/r that most PMs aren't modeling yet.
Northland upgrades to Outperform — the first real buy-side signal in a stock that's been left for dead. They think the satellite and margin fears are overblown, and that Software & Services momentum is the real story. Stock is down 32% in six months, trading at its 52-week low (SUNDAY CLOSE ~$35). Northland keeps PT at $52 — that's nearly 50% upside from here.
"The firm views these concerns as misguided" — Northland's call is essentially a contrarian bet that the memory margin squeeze is transitory and that the S&S gross margin record they're guiding for in Q3 changes the narrative.
Q2 print was solid: REVENUE $293.3M (BEAT BY $3.3M), EPS $0.47 vs $0.41 est. But the market fixated on guidance and appliance margin pressure. Northland says that's the wrong frame — the rate of change in software is the real lever. Worth a look if you think the selloff has over-corrected.
Cantor Fitzgerald reiterates Neutral, $340 PT — TXN is the consensus analog long (everyone already owns it). Bull case is well-rehearsed: data center power exposure, capacity leverage post-300mm ramp, FCF inflection, H2 pricing uptick. A beat-and-raise is baked in. The question Cantor is asking: can seasonal+ performance actually clear the bar of current expectations and positioning? Probably not.
“Primary pushback to the bullish thesis centers on the sustainability of 90% year-over-year data center growth seen in the first quarter.”
Valuation is full at 48.4x P/E, 4.48x PEG. Other houses are incrementally positive (MS upping estimates, Stifel Buy $360, BofA calling recent dip a temp adjustment), but that’s just more consensus-building. The risk/reward here is tight — you need the print to be perfect to justify the multiple.
Buy the dip narrative gaining real traction. Piper Sandler raised PT to $11 (from $9), Overweight, calling the Statsig partnership an "effective acquisition" that gave Amplitude IP, brand value, and customer contracts. The key number: Q2 checks surged 62% vs 27% last quarter — that’s a rate-of-change signal, not just static ARR. The initial $16M in Statsig ARR likely understates value because it excludes contracts with termination-for-convenience clauses and any cross-sell is pure incremental.
"The partnership was effectively an acquisition that gave Amplitude intellectual property, brand value, and customer contracts."
Raymond James also chimed in with a Strong Buy and $10 PT, citing favorable risk/reward and accelerating growth. Market cap sits at $1.3B — not cheap on a trailing revenue of $357M (3.6x), but the 73% gross margin and revised FY26 guidance to $400M midpoint (16.5% y/y) suggest operating leverage is still early innings. Statsig’s $1.1B acquisition by OpenAI validates the space. If checks hold, this is a story of TAM expansion, not just a one-time boost.
Morgan Stanley pulls the ripcord. Downgraded to Equalweight from Overweight, PT to $66 from $73. The core thesis they bought in December 2024 – that search would drive a growth inflection on GenAI – hasn’t materialized. Growth is stable (17% LTM revenue), but the inflection is not there. And now the narrative is getting worse: open source observability lane is losing share, SIEM is a knife fight (PANW, CRWD, DDOG all spending aggressively), and exec departures + restructuring push the recovery timeline out. Valuation is cheap (stock at $62.74, -17% YTD, -28% 1yr), but cheap doesn't matter if growth can't re-accelerate.
"We are less confident that a positive inflection in growth will materialize over the near-to-medium term." – Morgan Stanley
Other analysts are hedging, not doubling down. UBS cut PT to $85 (Buy), DA Davidson to $60 (Neutral), Rosenblatt to $83 (citing execution uncertainty from restructuring). Piper Sandler kept Overweight at $85 after meetings, but that's the bull case outlier. The cluster of PTs ($60-85) vs current price shows a wide dispersion – typical of a name where the bull/bear debate is unresolved. Cloud revenue decel to 20% YoY (missed whispers of 21% and $220M) is the immediate pain point. SIEM competition is structural, not cyclical. Not a stock to catch a falling knife unless you see a catalyst – and the next one (FQ1 results?) is months away.
Morgan Stanley throws in the towel. Downgrade to Underweight, PT slashed to $145 from $185 (stock at $147). The core problem: HCM growth is structurally slowing — 13% in FY26, modeled to 9% by FY28. FINS still chugging at 20%, but the overall subscription CAGR of 12-13% means flattish share. AI monetization? Still in pilot. Management admitted Q1 was juiced by Q4 slippage — H2 durability is the test. The old margin framework is dead; Analyst Day will bring a new one, but near-term expansion is slower. Valuation doesn't help either: 23x CY27 GAAP P/E is a premium to ADSK, CRM, SAP, INTU, ADBE.
"The prior medium-term operating framework is now being retired. Management noted margin expansion will be at a slower pace near term than previously communicated."
Other calls are mixed (CLSA Underperform, Monness Buy on valuation, Cantor Overweight) but the MS downgrade is the one that matters — it's the macro read on deceleration, not a micro opinion. The PEG of 0.55 and 76% gross margins are the bull case, but growth inertia is the bear case. Right now the stock is hugging the PT — not much margin of error.
Bernstein sticking to their guns with Underperform despite raising PT to $140 — that’s 13% downside from here. Meanwhile JPM just upgraded to Overweight at $180 (Chigusa Katoku citing short-cycle inflection + AI datacenter demand). The divergence is the story: bulls see the Microsoft EBO partnership and compounding industrial recovery; bears see an $84B market cap that still carries massive PFAS litigation tail risk and a history of under-investing in R&D.
"The firm said it remains concerned longer-term around research and development spending and PFAS-related issues."
That’s the crux. Bernstein acknowledges EBO + Microsoft is real progress, but they’re not buying the re-rate at 20x+ earnings when the legal and capital allocation overhang hasn’t cleared. The PT hike from $131 to $140 is purely mechanical — model updates off the data center thesis, not a change in conviction. Against the tape ($161), that’s a loud underweight signal from a shop that’s been right about the congested sideline debate.
TWLO is a standout in a miserable software tape. The infrastructure vs. applications divide is real — Twilio sits on the right side, and the buyside is piling in. Citizens lifted PT to $250 (from $210), but the real signal is the broader cluster: Mizuho at $240, Stifel at $260 post-upgrade, and Goldman's $300 initiation. That's a $240-300 range from credible names, all landing above the current $207 print. Stock is UP 45% YTD (vs. IGV -10%), and the narrative is shifting from "can they stabilize" to "how fast can they accelerate."
The consolidated thesis: infrastructure spending is re-accelerating, Twilio's Conversations and data tools are the AI hook, and developer adoption is sticky — Goldman flagged that 50% of the Forbes 50 AI startups were Twilio customers as of Sep 2024. The risk is that software broadly is still in a bear market (33 of 45 Citizens names down YTD), but Twilio is one of the 12 that's working. We like the r/r given the multiple compression tailwind is now a tailwind, not a headwind.
"Software consists of two subsectors: infrastructure and applications. Infrastructure is in a far better position, with 8 of the 15 infrastructure companies in Citizens’ coverage having traded up." — Patrick Walravens, Citizens
Verdict: The commercial aero ramp is real and accelerating. Park Aerospace crushed Q1 (FY27), with REVENUE $18.3M (+19% YoY, high-end of guide) and ADJ EBITDA $4.6M (+54% YoY). The CEO used the word "Juggernaut" to describe the aircraft build – and the stock is already up ~60% YTD, lapping the XAR (+6.6%). At 57x trailing earnings and a $682M market cap, this is a story about rate-of-change in narrowbody production, not current P/E.
Chairman and CEO Brian Shore stated "now we’re saying the Juggernaut is here" regarding the commercial aircraft ramp the company had previously promised.
After-hours action confirms the street is still playing catch-up on this cycle. If you're positioned for Boeing/737 MAX and Airbus A320 ramp, PKE is the purest small-cap proxy. Keep your stop tight – one airframe delay and this thing gives back 20%.
MS throws cold water on the AI trade. Downgraded FROG to Equalweight (from Overweight) while lifting the PT to $95 from $80. Not a fundamental call – they still love the story (cloud rev reaccelerating to 50% YoY, net retention at 120%, security products gaining traction). It's a valuation call. Stock is UP MORE THAN 100% SINCE MARCH, now trading near the 52-week high. The entire AI-assisted dev tools thesis is priced in, and the margin for error is razor thin as cloud revenue comps stiffen in coming quarters.
"The stock’s strong move since March, up more than 100%, raises expectations and leaves less margin for error, particularly as cloud revenue is set to face tougher year-over-year comparisons."
The bull case still has fans. Guggenheim raised PT to $105, UBS to $110 (Buy), Benchmark started at $100 (Buy). Cantor stuck at $80 (Overweight). The cluster of PTs from $95–$110 tells you the fundamental trajectory is intact – Q1 revenue growth accelerated to 26% YoY, cloud reaccel to 50%, net retention improving to 120%. Security products (Curation, Xray, Advanced Security) are gaining traction. The Canada federal government listing adds a channel tailwind.
The bear case is about multiple, not business quality. Excess consumption above commitments hasn't converted into larger contract commitments yet. Growth could moderate simply from comps. At current levels (~$90, near the $99 high), the stock leaves no room for a deceleration miss. Guidance is conservative, but sustained estimate revisions are now required for further upside – not just thesis validation.
Key takeaway: Great company, rich price. The r/r has flipped from asymmetric reward to balanced risk. Best entry on a pullback or after the next cloud revenue print confirms the reacceleration isn't fading.
Verdict: JPM stepping aside on valuation, but the tape isn't uniformly bearish.
Downgraded to Neutral (from Overweight), PT sliced to $714 from $805. That's a 13% haircut on the multiple – 42x from 46x on FY28E pro forma EPS, discounted back a year. Stock sits at $632, up 59% in twelve months. JPM sees "approximately balanced" r/r at current levels and prefers other EPC names under coverage.
The CFO bus tour message was classic Quanta: "elimination of uncertainty across labor, schedule, supply chain and cost."
"The company emphasized that its value proposition is the elimination of uncertainty across labor, schedule, supply chain and cost."
But don't bury the counterpoints. Oppenheimer upgraded to Outperform with an $800 target (yes, above JPM's old PT). Stifel reiterated Buy, citing transmission/distribution and renewables positioning. So the divergence is real – JPM is the valuation hawk, others are sticking with the secular grid build thesis.
Air permits for NiSource remain the gating item (late summer/early fall timeline – full speed after that). Combined-cycle gas turbines? Nothing in backlog, meaningful revenue a 2027+ story. Verticals buildout (6.7M sq ft manufacturing/logistics) is a labor multiplier, not a near-term catalyst.
Bottom line: PWR is no longer a clear long at these levels for the 20-year veteran. The easy 59% is behind us. You're now paying for a 2027 story with 2026 multiples. Better r/r elsewhere – unless you believe the backlog acceleration in H2 2026 overwhelms the valuation math.
UBS stays Buy ($250) but the near-term setup stinks. Partner checks show a more measured tone – AI adoption is building, upmarket momentum is real, but a weak apps spending environment and immature AI monetization are dragging. UBS doesn't see much upside to Q2 estimates and thinks HUBS will likely reiterate ~17% constant currency revenue guidance. Second-half acceleration? "increasingly challenging." At 11x CY27 EV/FCF, the multiple is cheap-ish for a reason.
"The firm views the current headwinds as largely reflective of broader seat-based apps software trends rather than HubSpot-specific issues."
That's a polite way of saying "macro is the problem, not product." But that also means no idiosyncratic catalyst to break out. Stock is down 58% in a year – the narrative has shifted from growth compounder to a low-visibility name that needs a macro all-clear to re-rate. Bull case rests on AI driving a long-tail SMB upgrade cycle; bear case says it's just another seat-based app getting crushed by optimization. UBS is holding the line but the tone is cautious. Not a high-conviction Buy – more of a "cheap enough to wait" stay.
VERDICT: MORGAN STANLEY THROWS IN THE TOWEL – downgrades to Equalweight, PT slashed to $33 from $50. The operational turnaround story played out but didn’t attract incremental buyers. Now the bull case rests entirely on AI-driven growth acceleration, and MS thinks that will take time in risk-averse accounting end-markets. Stock down 42% in six months. Broader analyst cluster now sits at $26-36 (BofA $26, DA Davidson $30, Cantor $36) – no one sees a near-term catalyst.
"Accounting requires high levels of accuracy, controls, and auditability, which means it will take time for risk-averse buyers to get fully comfortable adopting and scaling new AI products in this space." – Morgan Stanley
The fundamental beats (Q1 EPS $0.56 vs $0.45 est, rev $183M vs $181M) are noise in the face of the narrative shift. Until Verity AI converts pilots to scaled deployments – and that's quarters away – this stock stays dead money.
Bullish read-through from the Databricks fundraise. Jefferies lifted SNOW to $310 from $300, maintaining Buy. The logic: Databricks just raised $3B at a $188B valuation — a 40% premium to its December 2025 number. That implies ~17x FY28 revenue assuming 65% CAGR. Snowflake, by contrast, trades at ~13x FY28 revenue on a $100B EV. Even a 15x multiple gets you to $310. Street is already pricing in upside — UBS sits at $370 on the AI revenue story. CEO's new comp package (up to $448M tied to hitting $184B market cap) signals board confidence, not just a payday.
"Assuming a 65% revenue compound annual growth rate from fiscal year 2026 to fiscal year 2028, the Databricks valuation implies approximately 17 times fiscal year 2028 revenue. Snowflake currently trades at approximately 13 times fiscal year 2028 revenue on a $100 billion enterprise value."
The Databricks comp is the cleanest near-term catalyst — not just a "rising tide" argument but a concrete valuation reference point. SNOW's 31% revenue growth is real, though the Databricks rivalry in data warehousing (they just posted $1.5B ARR in that segment) remains the overhang. For now, the multiple gap gives PMs room to run. Stock at $274, near 52-week high of $285. Momentum favors a retest.
VERDICT: BUY-SIDE INFRASTRUCTURE PLAY DISGUISED AS A CONCRETE PUMPER. Texas Capital initiates with a $15 target, 43% upside from here. The thesis is simple: data center and semiconductor plant demand acts as the growth catalyst, offsetting the near-term residential/commercial drag. The stock’s already rallied 75% in six months — this isn’t a deep value call, it’s a rate-of-change bet on non-resi spending.
“The company should reach an inflection point driven by increasing demand from data centers, semiconductor plants and infrastructure spending — more than offsetting near-term softness in residential and light commercial markets in 2026.”
The analyst also likes the consolidation story in a fragmented market — M&A into adjacent services (Eco-Pan) with cross-sell. Q2 FY2026 already showed a beat: EPS $0.04 vs $0.01 expected, revs 11% above consensus. Momentum is real. Risks? Light commercial stays soft longer, or data center capex pauses. But right now r/r skews north.
Downgrade on valuation, not fundamentals. Jefferies cuts DDOG to Hold (from Buy), PT to $280 from $210. The stock is up 94% YTD and the AI beneficiary / category leader thesis has "largely played out." Growth re-accelerated from 25% to 32% YoY (Q1 2026 vs Q1 2025), but the valuation no longer offers a forgiving entry. At ~18x EV/CY27 revenue, DDOG trades at a four-turn premium to Snowflake. That leaves zero margin for error.
"At approximately 18 times enterprise value to calendar year 2027 revenue, Datadog trades at a four-turn premium to Snowflake, leaving little cushion for any execution slippage." — Brent Thill, Jefferies
The broader analyst backdrop is mixed but trending optimistic on the bull side. JMP, UBS, and Benchmark all raised PTs to a new cluster of $311–330 (Benchmark's $330 is Street-high). That crowd is leaning on infrastructure strength, AI adoption, and product-led growth. On the bear side, Bernstein downgraded to Market Perform on slowing demand signals in certain verticals and caution around Q3 prints. Net net: everyone loves the story, but the TRADE is getting crowded. Jefferies wants a better entry. So do we — at ~$263, the r/r is blurred. Wait for a pullback or a catalyst that resets the premium.
MORGAN STANLEY FLIPS TO UNDERWEIGHT – PT cut to $9 from $10 (stock at $10.34). Thesis: AI is a net negative for PagerDuty, not a tailwind. MS’s proprietary framework puts PD in the bottom quintile for moat against AI-native entrants and middling on its own AI adaptation journey. The bull case (cheap valuation at 5x P/E) doesn't offset the structural headwinds: seat compression, platform consolidation, and encroachment from observability/ITSM suites (Datadog, ServiceNow) and narrow AI startups.
"PagerDuty screens in the bottom quintile of its Software Evaluation Framework, with a weak moat score and a middling journey score."
RBC did bump PT to $9 from $8 last week on stabilization vibes, but that’s noise against the downgrade. Stock down 17% YTD vs SPX +9%. The bull-bear skew is negative, and MS sees more downside. Not a value trap – a value mirage.
Morgan Stanley throws in the towel. Downgraded to Equalweight from Overweight, PT slashed to $111 from $130. Stock sits at $101.34 — 11.56x earnings (cheap on the surface, but that's the trap). The call: MS thought the market was missing NICE's CCaaS positioning and relative profitability. They were wrong. Growth hasn't accelerated despite the Cognigy acquisition, channel builds, and deliberately lower margins to fund organic reinvestment.
The problem? All that reinvestment is crushing forward FCF expectations. And competition is piling on — hyperscalers, UCaaS vendors, AI-native upstarts all sniffing around the same CX wallet.
"Management’s decision to organically reinvest to support growth investments has resulted in meaningful reductions to forward free cash flow expectations, creating a challenging setup for re-rating until stronger growth materializes."
Elsewhere, BofA cut PT to $165 (still Buy), DA Davidson upgraded to Buy, Citizens reiterated Outperform at $170. So the Street is split. But the rate of change in fundamentals is negative — cloud revenue growth guidance trimmed to 13-15% from 14-15% this year. AI ARR up 66% y/y is the shiny object, but the core deceleration is real.
Not a clean setup. Cheap multiples don't matter when the narrative is shifting against you.
Morgan Stanley threw cold water on RPD Tuesday – downgraded to Underweight from Equalweight with a $9 PT (stock at $11.95, so ~25% downside baked in). The thesis: AI-native competitors are eating the vulnerability management lunch, and RPD’s 1.2% revenue growth over the last 12 months is a flashing red light. The transition toward exposure management with real-time remediation? Not working.
"We see an unfavorable risk-reward profile and prefer companies that have successfully pivoted toward exposure management — specifically Tenable (TENB)."
Weiss’s note “AI-Natives: Challengers, or Creating Challenges, for Cyber” frames the dynamic. RPD looks cheap on a PEG basis (the whole ex-PANW/CRWD cyber cohort trades at 2.1x PEG vs 1.1x for broader software), but that’s a value trap if growth continues to decelerate. The sharp recent stock run (up into the report) made the r/r even worse.
Offset? Q1 beat (EPS $0.36 vs $0.30, revenue $210M vs $207.93M) and new CEO Wael Mohamed with an ops transformation mandate. Mizuho stays Neutral at $8. So the bulls will point to the beat and the new blood, but Morgan Stanley sees a structural AI headwind that a leadership swap alone can’t fix. For a PM: this is a show-me story at a time when the market is not forgiving slow-growth legacy security names.